MDL Role in Mass Tort Claim: A Complete Attorney’s Guide

Attorneys handling a mass tort claim face compounding challenges: hundreds or thousands of plaintiffs spread across multiple jurisdictions, mountains of medical records, duplicative discovery demands, and the pressure to secure maximum settlement value for each client. The MDL role in mass tort claim litigation exists precisely to address these complexities.

Multidistrict Litigation (MDL) is the federal procedural mechanism that consolidates geographically dispersed lawsuits with common factual questions into a single federal court for coordinated pretrial proceedings. For attorneys building a mass tort practice — or expanding into active litigation — understanding exactly how MDL works, when to use it, and how it affects your litigation strategy is not optional. It is foundational.

This guide breaks down the MDL process, its strategic advantages and limitations, key 2026 developments including new FRCP Rule 16.1, and how medical records review integrates with MDL practice to strengthen individual plaintiff outcomes.

What Is a Mass Tort Claim? Key Legal Foundations

A mass tort claim arises when a single product, drug, device, or act of corporate negligence causes similar injuries to a large group of people. Unlike class actions — where all plaintiffs are bundled into a single, uniform claim — a mass tort preserves each plaintiff’s individual case. Every claimant must prove their own injury, medical causation, and damages.

Mass tort claims most commonly arise from:

• Pharmaceutical drugs with undisclosed or underreported side effects
• Defective medical devices (mesh, joint implants, IUDs)
• Environmental and toxic exposure (PFAS, asbestos, paraquat)   
• Consumer product defects causing widespread physical harm

Because each plaintiff maintains an independent claim, mass tort litigation is resource-intensive. This is where the MDL role in mass tort claim management becomes indispensable — by organizing pretrial work across all cases without eliminating each plaintiff’s right to individual recovery.

How MDL Works in a Mass Tort Claim: Step-by-Step

The MDL process is governed by 28 U.S.C. § 1407 and administered by the Judicial Panel on Multidistrict Litigation (JPML). Here is how the process unfolds:

Step 1 – Petition for Consolidation:

One or more parties file a motion with the JPML requesting centralization of related federal cases. The JPML evaluates whether the cases share common factual questions and whether consolidation would serve the convenience of parties and promote judicial efficiency.

Step 2 – JPML Hearing & Transfer Order:

The Panel holds a hearing where attorneys argue for or against consolidation. If granted, the JPML issues a Transfer Order sending all qualifying cases to a single federal district court — the transferee court — presided over by a transferee judge.

Step 3 – Tag-Along Actions:

As new related lawsuits are filed in federal courts around the country, they are automatically subject to Conditional Transfer Orders (CTOs), joining the existing MDL docket as tag-along actions.

Step 4 – Case Management Structure:

The transferee judge establishes leadership (Plaintiffs’ Steering Committee, Lead Counsel), issues a Case Management Order, and coordinates discovery, motions, and hearings across all cases.

Step 5 – Coordinated Discovery:

Instead of every plaintiff independently requesting the same corporate documents or taking the same depositions, discovery is conducted once and shared across the docket via a shared document repository.

Step 6 – Bellwether Trials:

A small set of representative cases are selected and tried to verdict. These bellwether trials test liability theories, damages calculations, and jury reactions, generating data that informs global settlement negotiations.

Step 7 – Resolution:

Most MDL cases resolve through global settlements negotiated based on bellwether trial results. Cases that do not settle are remanded (sent back) to their original federal courts for trial.

MDL vs Class Action: Critical Differences for Attorneys

When evaluating litigation strategy for a mass tort claim, attorneys must understand the fundamental distinction between MDL and class action:

Feature	MDL (Mass Tort)
Legal Structure	Individual cases coordinated for pretrial; each plaintiff sues separately
Class Action	All plaintiffs bundled into one representative lawsuit
Plaintiff Control	Each plaintiff retains control over their individual claim and settlement decision
Uniform Outcome	Each plaintiff gets individualized damages based on their specific injuries
Damages	Individualized — can be significantly higher for seriously injured plaintiffs
Discovery	Coordinated and shared, but applies to all individual claims
Settlement	Global settlement framework, but individual negotiation for each plaintiff
Best For	Cases where injuries vary significantly in severity across plaintiffs

The key strategic implication: in cases involving serious, individually varying injuries — such as pharmaceutical cancer claims or medical device failures — the MDL structure typically produces better outcomes for plaintiffs than a class action, because damages are not averaged across the group.

The Role of Plaintiffs’ Steering Committees (PSC) in MDL

Once an MDL is established, the transferee judge appoints a Plaintiffs’ Steering Committee (PSC) — a leadership team of experienced attorneys who coordinate the litigation on behalf of all plaintiffs. Understanding the PSC structure is essential for any attorney working on a mass tort claim.

PSC responsibilities typically include:

• Managing and organizing coordinated discovery
• Retaining and preparing shared expert witnesses
• Filing common motions and responding to defense motions
• Selecting and preparing bellwether trial cases
• Negotiating global settlement frameworks   
• Communicating litigation updates to all participating attorneys

For attorneys who are not on the PSC but represent individual plaintiffs in the MDL, understanding how to work within — and leverage — the PSC’s work product is critical. Attorneys gain access to the discovery record, expert reports, and motions briefings developed by the PSC, dramatically reducing the work required to advance individual claims.

Bellwether Trials: How They Shape Mass Tort Settlements

Bellwether trials are one of the most strategically significant features of the MDL role in mass tort claim resolution. A bellwether trial is a representative case — selected from the MDL docket — that is tried to verdict before a jury. The results serve as a barometer for the litigation as a whole.

How bellwether trials influence settlement negotiations:

• Strong plaintiff verdicts signal high liability exposure and push defendants toward early, higher-value global settlements
• Defense verdicts reduce defendants’ urgency to settle and may trigger longer litigation timelines
• The specific damages awarded in bellwether cases establish data benchmarks that inform the compensation formula applied across the docket in global settlements   
• Multiple bellwether trials create a statistical picture of likely jury behavior that both sides use to calculate settlement risk

For attorneys managing individual plaintiff cases within an MDL, the outcome of bellwether trials directly affects the settlement value of their clients’ claims. Staying informed about bellwether trial scheduling, results, and the judge’s rulings on admissibility and expert testimony is essential case management practice.

Key Benefits of MDL in Mass Tort Claim Litigation

The MDL role in mass tort claim litigation delivers measurable advantages to attorneys representing plaintiffs:

• Elimination of Redundant Discovery: Corporate documents, depositions of key witnesses, and expert reports are produced once and shared across all cases — dramatically reducing per-case litigation costs
• Consistent Pretrial Rulings: A single judge issues rulings on common legal issues (admissibility of expert testimony, summary judgment standards), creating predictability across the docket
• Settlement Leverage: The sheer volume of cases consolidated in an MDL creates significant pressure on defendants to negotiate global settlements rather than litigate thousands of cases individually
• Shared Litigation Infrastructure: PSC-developed case management tools, document repositories, and expert frameworks are available to all participating attorneys
• Preservation of Individual Rights: Unlike class actions, each plaintiff retains the right to reject a global settlement offer and proceed to individual trial
• Economies of Scale for Medical Records Review: Coordinated discovery means medical records protocols, record organization standards, and chronology templates can be standardized across all plaintiff files

Notable Mass Tort MDL Cases and Settlement Outcomes

The following landmark MDL cases illustrate the scale and impact of Multidistrict Litigation in mass tort claim resolution:

• J&J Talcum Powder MDL (#2738): Currently the largest active MDL with over 67,000 pending cases as of early 2026. Plaintiffs allege long-term talc use caused ovarian cancer and mesothelioma. Cases rely heavily on oncology records and exposure timelines.
• Opioid Litigation MDL: Consolidated thousands of lawsuits against pharmaceutical manufacturers and distributors. Resulted in multi-billion-dollar settlements with several major defendants, with funds distributed to states and municipalities.
• Roundup (Glyphosate) MDL (#2741): Claims arising from cancer linked to glyphosate exposure. A global settlement for outstanding Roundup cases was reached in Missouri state court in early 2026, demonstrating the interplay between federal MDL and state court proceedings.
• AFFF (Firefighting Foam) MDL (#2873): Over 15,000 pending cases as of 2026, alleging PFAS chemical exposure caused cancers. Medical records documenting occupational exposure, cancer diagnoses, and latency periods are central to individual claims.      
• Hair Relaxer MDL (#3060): Over 11,400 pending cases alleging a link between chemical hair relaxers and uterine, ovarian, and hormone-related cancers — one of the fastest-growing MDLs currently active.

State-Level Alternatives: JCCPs vs Federal MDL

Not every mass tort claim proceeds through the federal MDL system. Many claims — particularly those filed entirely in state courts — are coordinated through state-level equivalents. California’s Judicial Council Coordination Proceedings (JCCPs) are the most prominent example, functioning similarly to federal MDLs by centralizing pretrial proceedings for related state court cases.

The relationship between state and federal proceedings in mass torts is increasingly strategic. As noted in 2026 legal analysis from DiCello Levitt, the default advice to “get your case into MDL” is no longer always sound strategy. In some litigations, state courts serve as leverage points — the Roundup global settlement, for example, was reached in Missouri state court, not in the federal MDL. Attorneys should evaluate whether a parallel state court strategy can accelerate resolution or increase settlement pressure on defendants.

2026 MDL Updates: New FRCP Rule 16.1 and What It Means

A significant development affecting the MDL role in mass tort claim litigation took effect on December 1, 2025: Federal Rule of Civil Procedure 16.1 — the first federal rule of civil procedure to expressly address MDL proceedings.

Key provisions and their strategic implications for attorneys:

• Early Case Management Conferences: FRCP 16.1 encourages transferee judges to conduct initial case management conferences early in proceedings and issue management orders promptly — reducing the delay that has historically plagued large MDLs
• Required Meet-and-Confer on Claim Verification: Parties must meet, confer, and report to the court on “how and when the parties will exchange information about the factual basis for their claims and defenses” — meaning plaintiff attorneys must be prepared to substantiate individual claims earlier in the process
• Implications for Plaintiff Attorneys: Attorneys must ensure client medical records are organized, complete, and clearly establish causation from the earliest stages of MDL enrollment. Incomplete or disorganized records at the FRCP 16.1 stage can create dismissal risk    
• Meritless Case Screening: The rule is partly designed to allow early identification and dismissal of claims lacking sufficient factual basis — reinforcing the importance of thorough medical records review before filing

As of early 2026, MDLs account for approximately two-thirds of all private civil cases in the federal court system, underscoring how central the MDL role in mass tort claim management has become to the federal judiciary.

How Medical Records Review Strengthens Your MDL Strategy

In an MDL, medical records are not a secondary concern — they are the foundation of each individual plaintiff’s case. Because MDL mass tort claims preserve individual injury and causation requirements, every plaintiff must produce documentation that establishes:

• Diagnosis of the alleged injury or condition
• Chronological timeline of product use or exposure
• Medical causation connecting the product to the injury
• Treatment history, costs, and prognosis     
• Pre-existing conditions that defendants may use to contest causation

With the implementation of FRCP 16.1, the pressure to have this documentation ready early has intensified. Plaintiff Fact Sheets — which MDL courts routinely require — demand detailed medical information that can only be accurately completed with a thorough medical records review.

Our medical records review services for attorneys are specifically designed for mass tort and MDL litigation. We provide:

• Medical chronologies that organize complex records into a clear causation narrative
• Narrative summaries tailored to the specific injury and product at issue
• Billing summaries that document economic damages for settlement negotiations
• Missing records identification to ensure no critical documentation gaps
• Expert medical opinions that support causation arguments

Whether you are enrolling new clients into an active MDL, responding to Plaintiff Fact Sheet requirements, or preparing for bellwether trial selection, organized and professionally reviewed medical records directly impact the value of each client’s mass tort claim.

Frequently Asked Questions: MDL and Mass Tort Claims

What triggers the formation of an MDL?

An MDL is formed when the Judicial Panel on Multidistrict Litigation (JPML) determines that multiple federal lawsuits share common questions of fact and that centralization would promote judicial efficiency. Any party to a related lawsuit — or the JPML itself — can initiate the consolidation process. The Panel considers the number of cases, geographic distribution, complexity of common issues, and whether informal coordination between courts is a viable alternative.

How long does an MDL mass tort claim take to resolve?

MDL timelines vary widely depending on the complexity of the litigation, the number of cases, and the pace of bellwether trials. Many large pharmaceutical MDLs take 5–10 years to reach global resolution. However, individual cases can sometimes be resolved faster through early settlement programs within the MDL. FRCP 16.1, effective December 2025, is designed to accelerate early case management and reduce unnecessary delay.

Can individual plaintiffs opt out of an MDL?

Yes — but with important limitations. Plaintiffs in a mass tort MDL retain individual claims and can reject global settlement offers. However, if a plaintiff’s case was filed in federal court, it will generally be transferred to the MDL for pretrial proceedings regardless of plaintiff preference. Opting out of a global settlement means the individual case is remanded to its original court for trial — an option that is strategically viable in high-value cases with strong causation evidence.

What are the three types of tort claims?

The three types of tort claims are:

• (1) Intentional torts — where harm is caused by deliberate conduct
• (2) Negligence torts — the most common basis for mass tort claims, where a defendant failed to meet a reasonable standard of care, and
• (3) Strict liability torts — where a defendant is held liable regardless of intent or negligence, most commonly applied in product liability mass torts involving defective drugs, devices, or consumer products.